EFFECTS OF LAROPIPRANT ON THE PHARMACOKINETICS (PK) OF ROSIGLITAZONE IN HEALTHY SUBJECTS

被引：0
|
作者：
Schwartz, J. I. [1 ]
Stroh, M. [2 ]
Gao, B. [1 ]
Liu, F. [1 ]
Rosko, K. [1 ]
Zajic, S. [2 ]
Sisk, C. McCrary [1 ]
Ruckle, J. [3 ]
Wagner, J. [1 ]
机构：
[1] Merck, Rahway, NJ USA
[2] Merck, West Point, PA USA
[3] Pacific Pharma Grp, Kailua, HI USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [1] Effects of sitagliptin on the pharmacokinetics (PK)of rosiglitazone in healthy subjects
    Mistry, Goutam
    Bergman, Arthur
    Luo, Wen-Lin
    Cilissen, Caroline
    Haazen, Wouter
    Wagner, John
    Herman, Gary
    DIABETES, 2006, 55 : A463 - A463
  • [2] Effects of Multiple Doses of Clarithromycin on the Pharmacokinetics of Laropiprant in Healthy Subjects
    Wang, Ying-Hong
    Schwartz, Jules I.
    Luo, Wen-Lin
    Jumes, Patricia
    Desai, Rajesh
    Wenning, Larissa A.
    Wagner, John A.
    Lai, Eseng
    CARDIOVASCULAR THERAPEUTICS, 2011, 29 (02) : 140 - 145
  • [3] Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects
    Park, JY
    Kim, KA
    Kang, MH
    Kim, SL
    Shin, JG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) : 157 - 162
  • [4] Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects
    Park, JY
    Kim, KA
    Shin, JG
    Lee, KY
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) : 397 - 402
  • [5] Effect of rifampin on the pharmacokinetics of rosiglitazone in Korean healthy subjects.
    Park, J
    Kim, K
    Jung, W
    Kim, S
    Shin, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P34 - P34
  • [6] Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment.
    Noveck, RJ
    Vargas, R
    Russo, R
    Bello, A
    Gajjar, D
    Grasela, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [7] Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects
    Lauring, Brett
    Dishy, Victor
    De Kam, Pieter-Jan
    Crumley, Tami
    Wenning, Larissa
    Liu, Fang
    Sisk, Christine
    Wagner, John
    Lai, Eseng
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (05) : 367 - 376
  • [8] Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
    Schwartz, Jules I.
    Stroh, Mark
    Gao, Bing
    Liu, Fang
    Rosko, Kimberly
    Zajic, Stefan
    Meehan, Alan J.
    Ruckle, Jon
    Lai, Eseng
    Wagner, John A.
    CARDIOVASCULAR THERAPEUTICS, 2009, 27 (04) : 239 - 245
  • [9] Pharmacokinetics (PK) and pharmacodynamics (PD) of lanoteplase in healthy subjects.
    Vachharajani, N
    Shyu, W
    Stouffer, B
    Raymond, R
    Liao, W
    Tay, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 180 - 180
  • [10] Pharmacokinetics (PK) and pharmacodynamics (PD) of oral insulin in healthy subjects
    Kidron, Miriam
    Raz, Itamar
    Schruefer, Christian
    Shwo, Herve
    Wolfensberger, Micha
    DIABETES, 2008, 57 : A127 - A127
12345